 Treatments will be followed by standard clinical parameters for evaluating the safety of a biologicvaccine product including standardized methods for local and systemic vaccine reactions, repeated vital signs and physical examinations, 12-month follow-up 6 months post-dose 3 for adverse events and concomitant medication changes, and monitoring of clinical laboratory values as clinically indicated. 